Skip to main content

Table 1 Cost parameters (in 2012 Canadian dollar per patient)

From: Cost effectiveness and value of information analyses of islet cell transplantation in the management of ‘unstable’ type 1 diabetes mellitus

Source of costs Mean SD RSD Distribution Hyperparameters Sourcea
Pre-transplant visit 569      University of Alberta Hospital
Transplantation (including initial medication, based on 4 day stay: 1 pre-op and 3 post-op) 91,414   15.0 % Log-Normal μ = 11.412029 University of Alberta Hospital
σ = 0.149166
Total costs per transplantation (including all costs in the 23 days after a transplantation) 94,765    (via input)   
Medication and follow-up (from day 4 post-op onward)
Tacrolimus (per month) 450   7.5 % Log-Normal μ = 6.106443 University of Alberta Hospital
σ = 0.074895
Mycophenolate mofetil (MMF; per month) 500   7.5 % Log-Normal μ = 6.211803 University of Alberta Hospital
σ = 0.074895
Alemtuzumab (once per transplant)b 0      University of Alberta Hospital
Basiliximab (once at 2nd transplant for about half of patients instead of Alemtuzumab) 3000      University of Alberta Hospital
Valganciclovir (for 14 weeks) 5000 375 7.5 % Log-Normal μ = 8.514389 University of Alberta Hospital
σ = 0.074895
Anakinra (total for remaining 3 days after discharge) 574 43 7.5 % Log-Normal μ = 6.349825 University of Alberta Hospital
σ = 0.074895
Immunosuppression (per cycle, drugs: see above) 713 53 7.5 % Log-Normal μ = 6.56667 Calculated via data from University of Alberta Hospital
σ = 0.074895
Generic immunosuppression (per cycle) 238 18 7.5 % Log-Normal μ =5.46808 Calculated as 1/3 of cost above (price reduction for generic version based on market prices)
σ = 0.074895
Costs for insulin therapy in graft survival state (per cycle) 64    (via input)   Calculated via data from [33] and based on [10] as 40 % of costs with intensive insulin therapy
Post-transplant check-up visit (at week 1, 2, at 6 months and 1 year and then once a year) 556 42 7.5 % Log-Normal μ = 6.31800 University of Alberta Hospital
σ = 0.074895
Total per cycle (per year) costs for immunosuppression, follow-up and insulin (if applicable)
Full graft function for the first 6 months 1886 (30,175)    (via inputs)   Calculated via data from University of Alberta Hospital
Full graft function after the first 6 months 747 (11,956)    (via inputs)   Calculated via data from University of Alberta Hospital
Partial graft function for the first 6 months 1950 (31,196)    (via inputs)   Calculated via University of Alberta Hospital data and [33]
Partial graft function after the first 6 months 811 (12,977)    (via inputs)   Calculated via University of Alberta Hospital data and [33]
Intensive insulin therapy
Average healthcare costs of treating people with newly diagnosed diabetes (first 10 years) per cycle (per year)
Without complications for type 1 and 2 diabetes 159 (2552) 12 7.5 % Log-Normal μ = 5.06920 Corrected data from [33]
σ = 0.074895
With complications for type 1 and 2 diabetes 602 (9632) 120 20.0 % Gamma α = 25.00000 Calculated from corrected data in [33]
β = 24.0796
Other costs (per occurrence)
Average extra costs of initial immunosuppressive or other complications 600 180 30.0 % Gamma α = 11.1111 Assumption based on [2] and expert opinion
β = 54.0000
Average extra costs of major immunosuppressive complications 6500 1300 20.0 % Gamma α = 25.0000 Assumption based on [2] and expert opinion
β = 260.0000
  1. Bold values were directly used as model inputs and for calculating mean, standard deviation (SD) and relative standard deviation (RSD; i.e., SD as percentage of the mean). Other values are rounded and were incorporated into bold values. Superscripts: a Source relates to mean values. SD values were the authors’ estimations due to lack of data. b At the time of our study it was provided at no charge through a compassionate release program